SELECTION/CONSTRUCTION AND CHARACTERIZATION OF NOVEL PEPTIDE AND RECOMBINANT PROTEIN AGENTS TARGETING INTERLEUKIN 13 RECEPTOR ALPHA 2 IN GLIOBLASTOMA MULTIFORME

Glioblastoma multiforme (GBM) is a primary brain tumor of dismal prognosis. Patients with GBM have a median survival rate of 14.5 months inspite of multimodality treatment involving surgery, radio- and chemotherapy. This warrants an intensive search for efficient new therapies. Interleukin 13 receptor alpha 2 (IL-13Rα2) is an internalized, plasma membrane receptor for IL-13. IL-13Rα2 is over-expressed in around 75 percent of GBM patients. One of our goals is to develop specific therapeutic delivery vehicles and imaging agents targeting IL-13Rα2.

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2011

Author dc:creator

• Pandya, Hetal Vinod

• blood-brain tumor barrier

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/33429

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/33429